Introduction
Veno-arterial extracorporeal membrane oxygenation (va-ECMO) is increasingly and successfully used to assist patients with refractory cardiogenic shock from different causes.
1 However, it is currently not known which patients would benefit most from ECMO support. Schmidt et al developed and validated the SAVE-score to predict in-hospital survival with an area under the receiver operating characteristics curve of 0.68. 2 The nature of cardiac failure (ie, isolated left, vs isolated right, vs biventricular heart failure) was not incorporated into this model. Since ECMO may hamper left ventricular unloading and worsen left ventricular pressure/volume relations 3 -6 , the presence of predominant left ventricular failure in patients on va-ECMO support may be associated with worse outcome. To study this hypothesis, we investigated outcome according to the presence of isolated left, vs isolated right, vs biventricular heart failure. 
Abbreviations: LM, left main coronary artery; LAD, left anterior descending coronary artery; RCA, right coronary artery; Cx, circumflex coronary artery, RV, right ventricular (failure); NS, not significant. * near-drowning (n = 3), sepsis (n = 1), unknown etiology (n = 1), status epilepticus (n = 1) 
Methods

Study design
Procedure
Patients received va-ECMO by bifemoral cannulation (n = 127, 96%) via percutaneous (Seldinger) or surgical access. The remaining patients had central (2%) or subclavian/femoral (2%) access. A 21-29 Fr multistage venous cannula was inserted into the right atrium and a 17-21 Fr arterial cannula was retrogradely introduced in the common femoral artery, followed by cannulation (6 Fr sheath) of the superficial femoral artery for leg perfusion. We used a PLS or Cardiohelp set (oxygenator and pump, Maquet Cardiopulmonary, Rastatt, Germany) to reach a blood flow of 3.5-5.0 L/min, aimed at stabilizing hemodynamics (SvO2 > 60%, mean arterial pressure ≥60 mm Hg, low lactate level and diminishing need for vasopressors) and at regular aortic valve opening. 
Abbreviations: ECPR, extracorporeal cardiopulmonary resuscitation; LV, left ventricle; IABP, intra-aortic balloon pump. Abbreviations: CVVH, continuous veno-venous hemofiltration; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; HTX, heart transplantation; LVAD, left ventricular assist device; LuTX, lung transplantation. * Improved RV function during ECMO (n = 2), temporary Levitronics RVAD (n = 2), postoperatively continued VA-ECMO support followed by weaning (n = 1). # According to cause of cardiac failure/diagnosis: AMI (50%), ACHF (42%), post cardiotomy (48%), cardiac allograft failure (50%), pulmonary embolism (62%), acute nonischemic heart failure (52%): P = NS. ¶ 90-day survival in patients receiving HTX 4/4 (100%), LuTX 2/2 (100%), LVAD 9/11 (82%).
Data collection
For each patient, the nature of cardiac failure was addressed by transthoracic echocardiography and classified prior to ECMO implantation as isolated left, isolated right, or biventricular heart failure. Isolated LV failure was defined as an LV ejection fraction <35% on echocardiogram with preserved RV function. Isolated RV failure was defined as an LV ejection fraction >35% and evidence for RV failure: a tricuspid annular plane systolic excursion <1.6 cm, or qualitatively assessed moderate or severe RV systolic dysfunction together with at least moderate tricuspid regurgitation, and dilated inferior caval vein.
Patients meeting both criteria for LV and RV failure were classified as biventricular heart failure.
Follow-up
Follow-up started at the day of ECMO insertion (baseline 
Results
A total of 132 va-ECMO patients were enrolled. Thirty-four patients (26%) had isolated LV failure, 29 (22%) had isolated RV failure, and 69 (52%) had biventricular failure ( significantly younger (p = 0.01). Based on the SAVE score, patients had a predicted survival between 20 and 30%. Forty-eight percent had a cardiac arrest during or leading up to va-ECMO implantation. Cardiac arrest occurred most frequently in patients with isolated RV failure (79%, p < 0.001). Thirty percent of patients had refractory cardiogenic shock despite another form of mechanical circulatory support, mostly IABP, at the time of va-ECMO insertion. Patients had moderately impaired renal function and elevated lactate levels. SvO2 was not routinely measured at baseline (missing data in 55%). The cause of cardiac failure was heterogeneous: acute myocardial infarction (most frequently isolated LV failure, of which 100% of the patients underwent emergent percutaneous coronary intervention of at least the culprit lesion), acute on chronic heart failure (most frequently biventricular failure), post cardiotomy (most frequently biventricular failure), post cardiac transplantation (always biventricular failure), pulmonary embolism (always RV failure), and other forms of acute heart failure (most frequently biventricular failure).
Overall use of va-ECMO increased throughout the years ( Table 2 ). Of note, extracorporeal cardiopulmonary resuscitation for pulmonary embolism only started in 2012. Most (64%) cannulas were implanted via the percutaneous (Seldinger) approach. In 30% of the patients, LV venting was performed, most frequently by an IABP, and most commonly in patients with isolated LV failure.
Overall, median duration of ECMO support was 6 [3] [4] [5] [6] [7] [8] [9] days, and 7 [4] [5] [6] [7] [8] [9] days in ECMO survivors ( Table 3) . Median length of hospital stay was 22 days, 38 [20-59] and 42 [23-59] days in ECMO and hospital survivors, respectively. Most patients were bridged to recovery, but 47 patients (36%) died on or soon after cessation of support ("bridge to palliation"). A minority was bridged towards long-term LVAD or transplantation. In-hospital and 90-day survival was lowest in patients with isolated LV failure (Table 3, Figure 1 ). There was no difference in 90-day survival in ECMO survivors (n = 86) between patients who were supported < = 6 days (33/43) vs >6 days (34/43, p = NS). 
Isolated right ventricular failure Total n = 11
Biventricular failure Total n = 31
19 (61%) -MOF (n = 11 -58%) -No recovery and contra-indication for Causes for death on ECMO support and in-hospital death (after weaning from support) are listed in Table 4 . In patients with isolated left ventricular failure, 7 patients had no recovery of LV function and were abstained because they had a contra-indication for LVAD, predominantly because of LV thrombus ( Table 5) . ECMO-related complications are listed in Table 6 . The presence of isolated left ventricular failure was an independent predictor for 90-day mortality ( Table 7) .
In patients who survived 90 days following ECMO implantation, long-term (4-year) survival was favorable (overall 95%; 80% vs 100% vs 94% in isolated left vs biventricular vs isolated right ventricular failure, respectively, p = NS).
Discussion
This is the first study reporting the impact of the nature of cardiac failure (isolated left vs isolated right vs biventricular failure) in the prediction of 90-day outcome in ECMO patients.
Previous studies have demonstrated a good outcome (hospital discharge rate up to 75%) in VA-ECMO for pure biventricular failure such as acute fulminant myocarditis 7 -10 , or right ventricular failure such as pulmonary embolism.
11 However, hospital discharge rates in predominant left ventricular failure such as acute myocardial infarction may be lower. In this study, the characteristics of heart failure, based on strict echocardiographic criteria, identified the subgroup of patients with isolated left ventricular failure as those with a poor prognosis. The explanation for this differential outcome is not completely clear. This may be explained by the fact that LV systolic dysfunction takes more time to recover or is irreversible as opposed to e.g. myocarditis and pulmonary embolism. However, in this study, we could not detect a correlation between cause of cardiac failure with outcome ( Table 3) . Of note, bifemoral ECMO increases afterload and therefore might impede LV unloading preventing LV recovery, resulting in a failing static left ventricle in which the aortic valve fails to open properly thereby inducing thrombus formation.
13
The presence of LV thrombus in 57% of patients with isolated LV failure who died on ECMO seems to corroborate with this hypothesis. Whether concomitant LV venting by IABP or axial flow circulatory support might prevent thrombus formation in an akinetic left ventricle and improve outcomes requires further research. 14, 15 This study questions whether va-ECMO is the right device for a patient with isolated left ventricular failure. Pure LV ventricular unloading (by means of percutaneous left ventricular mechanical support devices) might be more suitable because these devices reduce afterload, decreased LV volumes and thus unload the ventricle.
16 -18 Our study has several limitations. First, pulmonary artery catheter-derived measurements were lacking in most patients. Second, since we present observational data, conclusions can only be hypothesis-generating. Third, sample size is relatively small and our findings should therefore be confirmed in larger studies and should spur further research to identify underlying mechanisms.
In conclusion, isolated left ventricular failure was an independent predictor for 90-day outcome. This finding might be helpful in risk stratification and questions the routine use of va-ECMO in patients with refractory pure LV failure.
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